XML 71 R56.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Segment Data Segment Data - Revenues by Geographic Areas (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020
Segment Reporting Information [Line Items] |  |  |
Revenues | $ 18,870 | $ 19,131 | $ 16,074
Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 8,841 | 8,361 | 7,637
Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 5,564 | 6,530 | 4,675
Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 4,464 | 4,239 | 3,762
United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 10,722 | 10,371 | 9,161
United States | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 4,950 | 4,544 | 4,247
United States | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,732 | 2,980 | 2,337
United States | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 3,040 | 2,847 | 2,577
Non-US |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 8,148 | 8,760 | 6,912
Non-US | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 3,891 | 3,817 | 3,389
Non-US | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,833 | 3,550 | 2,337
Non-US | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,424 | 1,392 | 1,186
Medication Delivery Solutions | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 4,308 | 4,101 | 3,596
Medication Delivery Solutions | United States | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,483 | 2,253 | 1,979
Medication Delivery Solutions | Non-US | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,825 | 1,848 | 1,617
Medication Management Solutions | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,533 | 2,432 | 2,454
Medication Management Solutions | United States | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,935 | 1,863 | 1,865
Medication Management Solutions | Non-US | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 598 | 570 | 589
Pharmaceutical Systems | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,001 | 1,828 | 1,587
Pharmaceutical Systems | United States | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 533 | 428 | 404
Pharmaceutical Systems | Non-US | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,468 | 1,400 | 1,183
Integrated Diagnostic Solutions | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 4,185 | 5,225 | 3,532
Integrated Diagnostic Solutions | United States | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,190 | 2,477 | 1,872
Integrated Diagnostic Solutions | Non-US | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,995 | 2,748 | 1,659
Biosciences | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,379 | 1,305 | 1,143
Biosciences | United States | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 542 | 503 | 465
Biosciences | Non-US | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 838 | 802 | 678
Surgery | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,400 | 1,296 | 1,121
Surgery | United States | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,094 | 1,023 | 891
Surgery | Non-US | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 306 | 274 | 230
Peripheral Intervention | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,759 | 1,711 | 1,511
Peripheral Intervention | United States | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 960 | 931 | 871
Peripheral Intervention | Non-US | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 799 | 780 | 640
Urology and Critical Care | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,305 | 1,232 | 1,130
Urology and Critical Care | United States | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 986 | 894 | 815
Urology and Critical Care | Non-US | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | $ 319 | $ 338 | $ 315

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_InterventionalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationDeliverySolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationManagementSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PharmaceuticalSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_IntegratedDiagnosticSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_BiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PeripheralInterventionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_UrologyandCriticalCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |